Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Sana Biotechnology, Inc Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates August 08, 2024 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other May 21, 2024 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates May 08, 2024 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology to Present at May and June 2024 Investor Conferences May 06, 2024 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates February 29, 2024 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference February 28, 2024 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP February 13, 2024 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares February 12, 2024 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Announces Pricing of Upsized Public Offering February 08, 2024 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Announces Proposed Public Offering of Common Stock February 07, 2024 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies January 05, 2024 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting December 11, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System December 01, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology to Present at November and December 2023 Investor Conferences November 21, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes November 17, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis November 09, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates November 08, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting November 02, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M October 10, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology to Present at September 2023 Investor Conferences August 30, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates August 03, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting June 16, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology to Present at June 2023 Investor Conferences May 31, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional May 08, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates May 08, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology to Present at May 2023 Investor Conferences May 03, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting May 02, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology to Host Research & Development Day April 24, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting April 19, 2023 From Sana Biotechnology, Inc Via GlobeNewswire Tickers SANA Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.